GlassScriptPhysician profile
Ali H Griffin
NPI 1144643669
$8,692.04
in general payments reported to CMS, 2019-2025
33 companies · $3,767 in 2025
The $3,767 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $215 · 2023: $2,220 · 2024: $2,250 · 2025: $3,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,237.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,829.55 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $707.02 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $636.46 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Madrigal Pharmaceuticals | $599.38 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $529.90 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $521.19 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $484.65 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $454.48 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $336.47 | 2023-2025 | Livdelzi |
| Genzyme Corporation | $324.42 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $296.66 | 2022-2023 | Rebyota, Clenpiq |
| Abbott Laboratories | $238.97 | 2021-2022 | |
| Lilly USA, LLC | $176.42 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $155.29 | 2023-2025 | Ocaliva |
| Novo Nordisk INC | $144.77 | 2023-2025 | Wegovy, Saxenda |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $126.18 | 2023 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.78 | 2024-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $117.12 | 2025 | Vowst |
| Amgen INC. | $92.80 | 2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $90.49 | 2023 | Sutab, Suflave |
| Pfizer INC. | $84.46 | 2024-2025 | |
| Celgene Corporation | $80.11 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $78.92 | 2024-2025 | Iqirvo |
| Enterra Medical, INC. | $61.58 | 2023 | |
| Mallinckrodt Hospital Products INC. | $58.05 | 2024 | Terlivaz |
| Sandoz INC. | $41.50 | 2023-2024 | Hyrimoz |
| Celltrion USA INC. | $38.23 | 2025 | Vegzelma |
| Medtronic, INC. | $33.73 | 2022-2023 | Interstim |
| Alnylam Pharmaceuticals INC. | $32.52 | 2022-2025 | Givlaari |
| Exact Sciences Corporation | $31.12 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.77 | 2024 | Cyltezo |
| Merit Medical Systems INC | $16.05 | 2023 | Elation Balloon Dilator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.